# Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

> **NCT07070700** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 56 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)

## Interventions

- **DRUG:** QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- **DRUG:** Lenvatinib
- **PROCEDURE:** cryoablation

## Key facts

- **NCT ID:** NCT07070700
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07070700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07070700, "Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07070700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*